Hervycta 150 mg Injection
  1. Home
  2. Pharma Products
  3. Dr Reddy 's Laboratories Ltd
  4. Hervycta 150 mg Injection

Hervycta 150 mg Injection

Hervycta 150 mg Injection contains trastuzumab 150 mg, a targeted anticancer medicine used for HER2-positive cancers. It is administered by a qualified healthcare professional through intravenous infusion according to the oncologist’s treatment plan. Trastuzumab targets the HER2 protein and helps inhibit the growth of HER2-positive cancer cells.

BUY NOW

Category

Hervycta 150 mg Injection is used in the treatment of HER2-positive breast cancer and certain HER2-positive metastatic gastric or gastroesophageal junction cancers. Trastuzumab is a monoclonal antibody that binds to the HER2 receptor and blocks signaling pathways involved in cancer-cell growth and survival. The medicine may be administered alone or in combination with chemotherapy or other anticancer treatments depending on the prescribed regimen. The dosage and treatment schedule are determined by the treating oncologist based on the patient’s condition and response to therapy.

Technical Specification

Specification Details
Active Ingredient Trastuzumab
Strength 150 mg
Dosage Form Powder for Injection
Route Intravenous Infusion
Pack Size 1 Vial
Manufacturer/Marketer Dr. Reddy’s Laboratories Ltd.

Product Also Known As

Hervycta 150 mg Injection, Hervycta 150 Injection, Hervycta Trastuzumab Injection, Trastuzumab 150 mg Injection, Trastuzumab HER2 Cancer Injection, Trastuzumab Targeted Therapy Injection